1. Home
  2. CTKB vs FULC Comparison

CTKB vs FULC Comparison

Compare CTKB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$4.85

Market Cap

433.8M

Sector

Health Care

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$13.00

Market Cap

468.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTKB
FULC
Founded
1990
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.8M
468.1M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
CTKB
FULC
Price
$4.85
$13.00
Analyst Decision
Hold
Buy
Analyst Count
4
8
Target Price
$5.88
$16.38
AVG Volume (30 Days)
1.9M
2.6M
Earning Date
11-05-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$196,828,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2752.05
52 Week Low
$2.37
$2.32
52 Week High
$7.30
$15.74

Technical Indicators

Market Signals
Indicator
CTKB
FULC
Relative Strength Index (RSI) 47.20 61.65
Support Level $4.79 $12.56
Resistance Level $5.16 $15.32
Average True Range (ATR) 0.24 1.27
MACD -0.11 0.30
Stochastic Oscillator 9.57 60.90

Price Performance

Historical Comparison
CTKB
FULC

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Share on Social Networks: